© 2000 American Heart Association, Inc.
Atherosclerosis and Lipoproteins |
New Functional Promoter Polymorphism, CETP/-629, in Cholesteryl Ester Transfer Protein (CETP) Gene Related to CETP Mass and High Density Lipoprotein Cholesterol Levels
Role of Sp1/Sp3 in Transcriptional Regulation
From the Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 321 (C.D., J.C., M.R.), Hopital de la Pitié-Salpétrière, and Unité 525 (O.P., F.C.), Paris, France.
Correspondence to Dr Christiane Dachet, INSERM, Unité 321, Hopital de la Pitié-Salpétrière, 83 Bd de l’Hopital, 75651 Paris Cedex 13, France. E-mail cdachet{at}infobiogen.fr
Abstract—A new polymorphism located at position -629 (CETP/-629A/C) in the promoter of the cholesteryl ester transfer protein (CETP) gene is described. The -629A allele was associated with lower CETP mass (P<0.0001) and higher high density lipoprotein cholesterol (P<0.001) than the C allele in a sample of 536 control subjects from the ECTIM study. Transfection studies in HepG2 cells with a luciferase expression vector incorporating a 777-bp fragment of the CETP promoter and containing either A or C at position -629 showed significantly lower luciferase activity with the promoter fragment of the A allele (-25%, P<0.05). By gel-shift assay, DNA-protein interactions were evaluated in nuclear extracts of HepG2 cells with the use of 2 probes (A or C probe) composed of 20 bp of the promoter sequence surrounding the polymorphic site. Two specific complexes of distinct migration rate were identified with the A and the C probe. Competition with an excess of oligonucleotide containing the Sp1 consensus binding site showed that a protein(s) of the Sp transcription factor family was implicated in complex formation with the A probe but not with the C probe. Incubation with specific antibodies indicated that Sp1 and Sp3 bound specifically to the A probe. We introduced mutations in the -629-Sp1 binding site to test its functionality and to define the characteristics of transcription factor binding. We showed, by gel-shift assay, that no nuclear proteins bound to the mutated sequence. Transient transfection of HepG2 cells revealed that the expression of the mutated fragment was significantly increased compared with that of the A promoter fragment (25%, P<0.05). The mutated fragment displayed the same activity as that of the C promoter. These results indicate that Sp1 and/or Sp3 repress CETP promoter activity, whereas nuclear factors binding the C allele are without effect on promoter expression.
Key Words: cholesteryl ester transfer protein • gene polymorphisms • transcription factors • ECTIM • cardiovascular disease
This article has been cited by other articles:
 |
|
 |
|
  A. Thompson, E. Di Angelantonio, N. Sarwar, S. Erqou, D. Saleheen, R. P. F. Dullaart, B. Keavney, Z. Ye, and J. Danesh Association of Cholesteryl Ester Transfer Protein Genotypes With CETP Mass and Activity, Lipid Levels, and Coronary Risk JAMA, June 18, 2008; 299(23): 2777 - 2788. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Y Li, C. Zhang, F. W Asselbergs, L. Qi, E. Rimm, D. J Hunter, and F. B Hu Interaction between dietary fat intake and the cholesterol ester transfer protein TaqIB polymorphism in relation to HDL-cholesterol concentrations among US diabetic men Am. J. Clinical Nutrition, November 1, 2007; 86(5): 1524 - 1529. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Porchay-Balderelli, F. Pean, N. Bellili, R. Jaziri, M. Marre, F. Fumeron, and for the DIABHYCAR Study Group The CETP TaqIB Polymorphism Is Associated With the Risk of Sudden Death in Type 2 Diabetic Patients Diabetes Care, November 1, 2007; 30(11): 2863 - 2867. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Spielmann, A. S. Leon, D. C. Rao, T. Rice, J. S. Skinner, C. Bouchard, and T. Rankinen CETP genotypes and HDL-cholesterol phenotypes in the HERITAGE Family Study Physiol Genomics, September 11, 2007; 31(1): 25 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Singer, H. Holdaas, A. G. Jardine, B. Fellstrom, I. Os, G. Bermann, J. M. Meyer, and on behalf of the Assessment of Lescol in Renal Tra Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients J. Lipid Res., September 1, 2007; 48(9): 2072 - 2078. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. Thompson, L. S. Wood, E. H. Pickering, B. DeChairo, and C. L. Hyde High-density genotyping and functional SNP localization in the CETP gene J. Lipid Res., February 1, 2007; 48(2): 434 - 443. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Borggreve, H. L. Hillege, B. H. R. Wolffenbuttel, P. E. de Jong, M. W. Zuurman, G. van der Steege, A. van Tol, R. P. F. Dullaart, and on behalf of the PREVEND Study Group An Increased Coronary Risk Is Paradoxically Associated with Common Cholesteryl Ester Transfer Protein Gene Variations That Relate to Higher High-Density Lipoprotein Cholesterol: A Population-Based Study J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3382 - 3388. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Frisdal, A. H.E.M. Klerkx, W. L. Goff, M. W.T. Tanck, J.-P. Lagarde, J. W. Jukema, J. J.P. Kastelein, M. J. Chapman, and M. Guerin Functional interaction between -629C/A, -971G/A and -1337C/T polymorphisms in the CETP gene is a major determinant of promoter activity and plasma CETP concentration in the REGRESS Study Hum. Mol. Genet., September 15, 2005; 14(18): 2607 - 2618. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Borggreve, H. L. Hillege, B. H. R. Wolffenbuttel, P. E. de Jong, S. J. L. Bakker, G. van der Steege, A. van Tol, R. P. F. Dullaart, and on behalf of the PREVEND Study Group The Effect of Cholesteryl Ester Transfer Protein -629C->A Promoter Polymorphism on High-Density Lipoprotein Cholesterol Is Dependent on Serum Triglycerides J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4198 - 4204. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. B. Lloyd, M. E. Lira, L. S. Wood, L. K. Durham, T. B. Freeman, G. M. Preston, X. Qiu, E. Sugarman, P. Bonnette, A. Lanzetti, et al. Cholesteryl Ester Transfer Protein Variants Have Differential Stability but Uniform Inhibition by Torcetrapib J. Biol. Chem., April 15, 2005; 280(15): 14918 - 14922. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.M. Boekholdt, F.M. Sacks, J.W. Jukema, J. Shepherd, D.J. Freeman, A.D. McMahon, F. Cambien, V. Nicaud, G.J. de Grooth, P.J. Talmud, et al. Cholesteryl Ester Transfer Protein TaqIB Variant, High-Density Lipoprotein Cholesterol Levels, Cardiovascular Risk, and Efficacy of Pravastatin Treatment: Individual Patient Meta-Analysis of 13 677 Subjects Circulation, January 25, 2005; 111(3): 278 - 287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. de Grooth, A. H. E. M. Klerkx, E. S. G. Stroes, A. F. H. Stalenhoef, J. J. P. Kastelein, and J. A. Kuivenhoven A review of CETP and its relation to atherosclerosis J. Lipid Res., November 1, 2004; 45(11): 1967 - 1974. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.C. Shoulders, E.L. Jones, and R.P. Naoumova Genetics of familial combined hyperlipidemia and risk of coronary heart disease Hum. Mol. Genet., April 1, 2004; 13(90001): R149 - 160. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D Tobin, P. S Braund, P. R Burton, J. R Thompson, R. Steeds, K. Channer, S. Cheng, K. Lindpaintner, and N. J Samani Genotypes and haplotypes predisposing to myocardial infarction: a multilocus case-control study Eur. Heart J., March 2, 2004; 25(6): 459 - 467. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J Freeman, N. J Samani, V. Wilson, A. D McMahon, P. S Braund, S. Cheng, M. J Caslake, C. J Packard, D. Gaffney, and on behalf of the West of Scotland Study Group A polymorphism of the cholesteryl ester transfer protein gene predicts cardiovascular events in non-smokers in the West of Scotland Coronary Prevention Study Eur. Heart J., October 2, 2003; 24(20): 1833 - 1842. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Boekholdt and J. F. Thompson Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease J. Lipid Res., July 1, 2003; 44(6): 1080 - 1093. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Le Goff, M. Guerin, L. Petit, M. J. Chapman, and J. Thillet Regulation of human CETP gene expression: role of SP1 and SP3 transcription factors at promoter sites -690, -629, and -37 J. Lipid Res., July 1, 2003; 44(7): 1322 - 1331. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Blankenberg, H. J. Rupprecht, C. Bickel, X.-C. Jiang, O. Poirier, K. J. Lackner, J.u. Meyer, F. Cambien, L. Tiret, and AtheroGene Investigators Common genetic variation of the cholesteryl ester transfer protein gene strongly predicts future cardiovascular death in patients with coronary artery disease J. Am. Coll. Cardiol., June 4, 2003; 41(11): 1983 - 1989. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Anderson and J. F. Carlquist Genetic polymorphisms of hepatic lipase and cholesteryl ester transfer protein, intermediate phenotypes, and coronary risk: Do they add up yet? J. Am. Coll. Cardiol., June 4, 2003; 41(11): 1990 - 1993. [Full Text] [PDF]
|
|
|
|
|
|
W. Le Goff, M. Guerin, M. J. Chapman, and J. Thillet A CYP7A promoter binding factor site and Alu repeat in the distal promoter region are implicated in regulation of human CETP gene expression J. Lipid Res., May 1, 2003; 44(5): 902 - 910. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. V. van Venrooij, R. P. Stolk, J.-D. Banga, T. P. Sijmonsma, A. van Tol, D. W. Erkelens, and G. M. Dallinga-Thie Common Cholesteryl Ester Transfer Protein Gene Polymorphisms and the Effect of Atorvastatin Therapy in Type 2 Diabetes Diabetes Care, April 1, 2003; 26(4): 1216 - 1223. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Barter, H. B. Brewer Jr, M. J. Chapman, C. H. Hennekens, D. J. Rader, and A. R. Tall Cholesteryl Ester Transfer Protein: A Novel Target for Raising HDL and Inhibiting Atherosclerosis Arterioscler. Thromb. Vasc. Biol., February 1, 2003; 23(2): 160 - 167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.C. Mahaney, L. Almasy, D.L. Rainwater, J.L. VandeBerg, S.A. Cole, J.E. Hixson, J. Blangero, and J.W. MacCluer A Quantitative Trait Locus on Chromosome 16q Influences Variation in Plasma HDL-C Levels in Mexican Americans Arterioscler. Thromb. Vasc. Biol., February 1, 2003; 23(2): 339 - 345. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H.E.M. Klerkx, M. W.T. Tanck, J. J.P. Kastelein, H. O.F. Molhuizen, J. W. Jukema, A. H. Zwinderman, and J. A. Kuivenhoven Haplotype analysis of the CETP gene: not TaqIB, but the closely linked -629C->A polymorphism and a novel promoter variant are independently associated with CETP concentration Hum. Mol. Genet., January 15, 2003; 12(2): 111 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bansal, D. van den Boom, S. Kammerer, C. Honisch, G. Adam, C. R. Cantor, P. Kleyn, and A. Braun Association testing by DNA pooling: An effective initial screen PNAS, December 24, 2002; 99(26): 16871 - 16874. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Nagano, S. Yamashita, K.-i. Hirano, M. Ito, T. Maruyama, M. Ishihara, Y. Sagehashi, T. Oka, T. Kujiraoka, H. Hattori, et al. Two novel missense mutations in the CETP gene in Japanese hyperalphalipoproteinemic subjects: high-throughput assay by Invader (R) assay J. Lipid Res., July 1, 2002; 43(7): 1011 - 1018. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Brousseau, J. J. O'Connor Jr, J. M. Ordovas, D. Collins, J. D. Otvos, T. Massov, J. R. McNamara, H. B. Rubins, S. J. Robins, and E. J. Schaefer Cholesteryl Ester Transfer Protein TaqI B2B2 Genotype Is Associated With Higher HDL Cholesterol Levels and Lower Risk of Coronary Heart Disease End Points in Men With HDL Deficiency: Veterans Affairs HDL Cholesterol Intervention Trial Arterioscler. Thromb. Vasc. Biol., July 1, 2002; 22(7): 1148 - 1154. [Abstract] [Full Text] [PDF]
|
|